First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations
首次人体研究:萘普生非尼(LXH254)联合或不联合斯帕塔利珠单抗治疗伴有MAPK信号通路改变的晚期实体瘤成年患者
期刊:European Journal of Cancer
影响因子:7.1
doi:10.1016/j.ejca.2023.113458
Janku, Filip; Kim, Tae Min; Iyer, Gopakumar; Spreafico, Anna; Elez, Elena; de Jonge, Maja; Yamamoto, Noboru; van der Wekken, Anthonie J; Ascierto, Paolo Antonio; Maur, Michela; Marmé, Frederik; Kiladjian, Jean-Jacques; Basu, Sumit; Baffert, Fabienne; Buigues, Amparo; Chen, Chi; Cooke, Vesselina; Giorgetti, Elisa; Kim, Jaeyeon; McCarthy, Fiona; Moschetta, Michele; Dummer, Reinhard